In the past decade, advancements in scientific technologies such as imaging, new materials and large-scale omics analysis have fundamentally transformed the diagnosis and treatment of certain diseases. 

The application of artificial intelligence has also begun to revolutionize diagnosis, treatment, drug development and pre-clinical research of rare genetic diseases, with the practical adoption of AI algorithms in these areas.

This session on artificial intelligence and rare metabolic diseases will center on rare diseases while also addressing important conditions such as fatty liver disease, cardiovascular disease and COVID-19. 

It aims to explore the latest advancements in disease research empowered by AI, enhance the accessibility of AI-assisted diagnosis and treatment, improve rapid and precise diagnosis and treatment of metabolic diseases and contribute to the high-quality growth of China's healthcare industry.

Chair

Zhou Hongwen

Professor, The First Affiliated Hospital with Nanjing Medical University

Invited speakers & reports

Xue Yu

Hangzhou University of Science and Technology 

Report: Language models in PTM bioinformatics

Chen Liangyi

Professor, Peking University

Report: Developing living cell super-resolution imaging technology to elucidate clinical rare disease mechanisms

Chen Fengrong

Young researcher, Institute of Metabolism & Integrative Biology, Fudan University

Report: AI diagnostic system for nonalcoholic fatty liver disease

Chen Yang

Professor, Southeast University

Report: Research on AI in cardiovascular and cerebrovascular diseases

Zhao Yinghua

Jilin University

Report: Alterations in succinylation modifications mediated by host cells during novel coronavirus infection